TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Inclusion Criteria: Age between18 and 75 years; Has a diagnosis of HCC confirmed by radiology, histology, or cytology; Type I PVTT or type II PVTT; Child-Pugh class A; Eastern Cooperative Group performance status (ECOG) score of 0-1; No prior systemic therapy for HCC. Adequate hematologic and end-organ function; At least one measurable intrahepatic target lesion. Exclusion Criteria: Diffuse HCC; Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes (confirmed by histology, or pathology) are not eligible; Evidence of extrahepatic spread (EHS); Any condition representing a contraindication to TACE or I-125 seeds brachytherapy as determined by the investigators; Evidence or history of bleeding diathesis or any hemorrhage or bleeding event >CTCAE grade 3 within 4 weeks prior to randomization; Active or history of autoimmune disease or immune deficiency; Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding; A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment; Evidence of bleeding diathesis or significant coagulopathy; Pregnant or breastfeeding females; Significant cardiovascular disease; Severe infection, such as active tuberculosis; Serious medical comorbidities; History of organ or cells transplantation; History of other uncurable malignancies.